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Background: The aim of this study was to compare TAVI outcomes with the new-
generation Direct Flow Medical (DFM) versus the Medtronic CoreValve (MCV) and
Edwards SAPIEN XT (ESV) devices.
Methods: From November 2007 to March 2014 all consecutive patients who un-
derwent transfemoral TAVI with DFM, MCV or ESV in our center have been
included. Because of differences in baseline characteristics a propensity score
matching among patients treated in the same time span was performed. Endpoints
were deﬁned according to VARC-2 criteria at 30 days.
Results: Overall, 496 patients were included: 44 (8.7%) treated with DFM, 179
(36.9%) with MCV and 273 (54.4%) with ESV. Rigorous propensity-score matching
identiﬁed 41 patients in each group. A higher device success endpoint was observed in
DFM (DFM 100% vs. MCV 61% vs. ESV 85.4%; p < 0.001). This was attributed to a
signiﬁcantly lower incidence of moderate-to-severe post-procedural aortic regurgita-
tion (PPAR; 0% vs. 24.4% vs. 15.4%; p ¼ 0.014), valve embolization (0% vs. 7.3%
vs. 0%; 0.041) and need for a 2 valve implantation (0% vs. 7.3% vs. 0%; p ¼ 0.041).
Of note, a more frequent need of balloon post-dilation, secondary to moderate-to-
severe PPAR immediately after valve implantation, was observed with MCV and ESV
(0% vs. 39% vs. 34%; p < 0.001). No differences were present in post-procedural
mean gradient (7.5  4.4 vs. 6.5  5.8 vs. 4.9  4.1 mmHg; p ¼ 0.139). Interestingly,
DFM was associated with a trend to less acute kidney injury stage II or III (2.4% vs.
14.6% vs. 4.9%; p ¼ 0.081), this ﬁnding was probably related to a numerically lower
contrast medium dose used during DFM implantation (100  50.3 vs. 123.2  66.9
vs. 113.1  58.9; p ¼ 0.219). Conversely, incidence of permanent pacemaker im-
plantation with DFM was lower than MCV but higher as compared to ESV (17.1% vs.
34.1% vs. 7.3%; p ¼ 0.001). Finally, no differences were observed at 30 days in
cardiovascular mortality (0% vs. 2.4% vs. 0%; p ¼ 0.365) and early safety composite
endpoint (4.9% vs. 17.1% vs. 14.6%; p ¼ 0.203).
Conclusions: DFM was associated with higher rates of device success and a lower
incidence of PPAR. New generation devices solve several of the limitations of earlier
generation devices.
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Background: Mitral regurgitation (MR) is a common entity in patients with aortic
stenosis undergoing transcatheter aortic valve replacement (TAVR), but its inﬂuence
on outcomes remains controversial. The purpose of this meta-analysis was to assess
the clinical impact of and changes in signiﬁcant (moderate-severe) MR in patientsB204 JACC Vol 64/11/Suppl B j Sepundergoing TAVR, overall and according to valve design (self-expandable [SEV] vs.
balloon-expandable [BEV]).
Methods: All national registries and randomized trials published between 2002 and
2013 were identiﬁed and pooled using meta-analytical guidelines to establish the
impact of moderate or severe MR on mortality after TAVR. Studies reporting changes
in MR after TAVR on an individual level were electronically searched and used for
the analysis.
Results: Eight studies including 8015 patients (SEV: 3474 patients; BEV: 4492
patients) were included in the analysis. The overall 30-day and 1-year mortality was
increased in patients with signiﬁcant MR (OR: 1.49, 95% CI: 1.16-1.92; HR: 1.32,
95% CI: 1.12-1.55, respectively), but a signiﬁcant heterogeneity across studies was
observed (P< 0.05). The negative effect of MR on 1-year mortality was more evident
in patients who had received a SEV (HR: 1.62, 95% CI 1.23-2.14) than those who had
received a BEV (HR: 1.22, 95% CI 0.98 to 1.51). Changes in MR over time were
evaluated in 9 studies including 1278 patients. Moderate-severe MR (SEV: 326 pa-
tients; BEV: 192 patients) improved in 50.5% of the patients at a median follow-up of
180 (30-360) days after TAVR, and the degree of improvement was greater in patients
who had received a BEV (66.7% vs. 40.8% in the SEV group, P¼0.001).
Conclusions: Concomitant moderate-severe MR was associated with increased early
and late mortality following TAVR. A signiﬁcant improvement in MR severity was
detected in half of the patients following TAVR, and the degree of improvement was
greater in those patients who had received a BEV. The results of the present meta-
analysis provide further insight into the effects of and changes in MR in patients
undergoing TAVR, and this may be of help in the clinical decision-making process
and procedural planning for such a challenging group of patients.
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Background: The repositionable and fully retrievable Lotus Valve (Boston Sci-
entiﬁc, Natick, MA, USA) was designed to facilitate accurate positioning and mini-
mize paravalvular regurgitation in patients with severe aortic stenosis who are at high
or extreme surgical risk. The device is CE-marked based on favorable efﬁcacy and
safety outcomes at 30 days in the prospective, single-arm, multicenter REPRISE II
trial. This analysis will present the ﬁrst report of 1-year outcomes from the full cohort
of patients in REPRISE II.
Methods: The study enrolled 120 symptomatic patients aged 70 years at 14 centers
in Australia and Europe. Patients had severe calciﬁc AS and were deemed to be at high
or extreme risk for surgery based on assessment by the Heart Team.
Results: The mean age was 84.45.3 yrs, 57% (68/120) were female, and mean STS
Score was 7.14.6. The mean baseline aortic valve area was 0.70.2cm2, and the
mean aortic valve pressure gradient was 46.415.0mmHg. All patients were suc-
cessfully implanted with a Lotus Valve and 6-month follow-up data or death was
available in 99.2% (119/120). The primary performance endpoint of 30-day mean
aortic valve pressure gradient was 11.55.2mmHg, as assessed by an independent
core lab, and was signiﬁcantly less than the performance goal of 18 mmHg
(P< 0.001). The primary safety endpoint of 30-day all-cause mortality was 4.2%. At
6 months, the VARC Safety Composite rate was 20.2% (24/119), all-cause mortality
was 8.4% (10/119), disabling stroke was 3.4% (4/119), disabling bleeding was 5.0%
(6/119), with no repeat procedures for valve-related dysfunction. A total of 29.4%
(35/119) patients had new permanent pacemaker implantation due to new or worsened
conduction disturbance. Mean 6-month aortic valve gradient was 11.44.6mmHg and
mean aortic valve area was 1.70.4cm2. By independent core lab adjudication, 80.9%
patients had no/trivial paravalvular aortic regurgitation at 6 months.
Conclusions: The Lotus Valve has demonstrated minimal paravalvular regurgitation
and low rates of death and stroke at 6 months. One-year results for the full 120 patients
in the REPRISE II trial will be presented for the ﬁrst time at TCT 2014.tember 13–17, 2014 j TCT Abstracts/Valvular disease - Aortic: TAVR
